The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application
1 other identifier
interventional
18
1 country
1
Brief Summary
Patients undergoing major surgery, trauma and burns are prone to develop an exacerbated inflammatory response, which is potentially lethal to the individual. Recently our group demonstrated that administration of high fat feeding prior to hemorrhagic shock attenuates severe inflammation, gut barrier loss and hepatic damage. High fat feeding releases cholecystokinin in the gut, which stimulates the autonomous nervous system and subsequently activates the efferent vagus nerve. The activated efferent fibers inhibit tissue macrophages via binding of acetylcholine to the alpha7-nicotinergic receptor. In this study the cholecystokinin release in healthy volunteers is monitored in response to low fat and high fat food products.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for early_phase_1
Started Mar 2007
Typical duration for early_phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2007
CompletedFirst Submitted
Initial submission to the registry
May 1, 2007
CompletedFirst Posted
Study publicly available on registry
May 2, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2010
CompletedMarch 31, 2010
March 1, 2010
2.9 years
May 1, 2007
March 30, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
CCK-release
two hours
Interventions
Four nutritional interventions on four separate days per test person
Eligibility Criteria
You may qualify if:
- Healthy males and females
- \> age \<55
You may not qualify if:
- Gastrointestinal diseases
- Inflammatory conditions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Maastricht
Maastricht, Limburg, 6200 MD, Netherlands
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Jan-Willem Greve, professor
Maastricht University Medical Center
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 1, 2007
First Posted
May 2, 2007
Study Start
March 1, 2007
Primary Completion
February 1, 2010
Study Completion
March 1, 2010
Last Updated
March 31, 2010
Record last verified: 2010-03